Jean S. Beebe

Combination Therapy Enhances the Inhibition of Tumor Growth with the Fully Human Anti–Type 1 Insulin-Like Growth Factor Receptor Monoclonal Antibody CP-751,871

Bruce D. Cohen, Deborah A. Baker, Catherine Soderstrom et al. · Clinical Cancer Research · 2005 · 361 citations · Full text

Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis

Melinda Gooderham, Seth Forman, Robert Bissonnette et al. · JAMA Dermatology · 2019 · 232 citations · Full text

Randomised trial and open-label extension study of an anti-interleukin-6 antibody in Crohn’s disease (ANDANTE I and II)

Silvio Danese, Séverine Vermeire, Paul Hellstern et al. · Gut · 2017 · 174 citations · Full text

Increased Serum Enzyme Levels Associated with Kupffer Cell Reduction with No Signs of Hepatic or Skeletal Muscle Injury

Zaher A. Radi, Petra Koza‐Taylor, R. R. Bell et al. · American Journal Of Pathology · 2011 · 137 citations · Full text

Inflammation, No Signs, Hepatology +11

Pharmacological characterization of CP-547,632, a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for cancer therapy.

Jean S. Beebe, Jitesh P. Jani, Elisabeth Knauth et al. · PubMed · 2003 · 128 citations

Cancer Therapy, Pharmacological Characterization, Tumor Biology +21